These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 38885297)
1. Effects of Dapagliflozin on Body Composition and Its Relation to Hemodynamics in Heart Failure With Preserved Ejection Fraction. Naser JA; Tada A; Harada T; Reddy YNV; Carter RE; Testani JM; Jensen MD; Borlaug BA Circulation; 2024 Jun; 149(25):2026-2028. PubMed ID: 38885297 [No Abstract] [Full Text] [Related]
2. Dapagliflozin (Farxiga) - a new indication for heart failure. Med Lett Drugs Ther; 2020 Jun; 62(1601):102-103. PubMed ID: 32724023 [No Abstract] [Full Text] [Related]
4. NICE guidance on dapagliflozin for chronic heart failure with reduced ejection fraction. Adler AI; Douch E; Dunning L; Elliott N Lancet Diabetes Endocrinol; 2021 May; 9(5):261-263. PubMed ID: 33713596 [No Abstract] [Full Text] [Related]
5. Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. Docherty KF; Jhund PS; Anand I; Bengtsson O; Böhm M; de Boer RA; DeMets DL; Desai AS; Drozdz J; Howlett J; Inzucchi SE; Johanson P; Katova T; Køber L; Kosiborod MN; Langkilde AM; Lindholm D; Martinez FA; Merkely B; Nicolau JC; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Tereshchenko S; Verma S; McMurray JJV Circulation; 2020 Oct; 142(17):1623-1632. PubMed ID: 32883108 [TBL] [Abstract][Full Text] [Related]
6. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500 [TBL] [Abstract][Full Text] [Related]
7. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure. Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613 [TBL] [Abstract][Full Text] [Related]
9. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients. Tanashat M; Manasrah A; Abouzid M Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097 [TBL] [Abstract][Full Text] [Related]
10. Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events. Packer M Circulation; 2019 Aug; 140(6):443-445. PubMed ID: 31381418 [No Abstract] [Full Text] [Related]
11. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173 [TBL] [Abstract][Full Text] [Related]
12. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. Omar M; Jensen J; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Möller S; Ali M; Gustafsson F; Køber L; Borlaug BA; Schou M; Møller JE J Am Coll Cardiol; 2020 Dec; 76(23):2740-2751. PubMed ID: 33272368 [TBL] [Abstract][Full Text] [Related]
13. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial. Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976 [TBL] [Abstract][Full Text] [Related]